U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07240844) titled 'Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy' on Sept. 28.
Brief Summary: This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.
Study Start Date: Nov. 24
Study Type: INTERVENTIONAL
Condition:
Amyloid Cardiomyopathy
Intervention:
DRUG: Enavogliflozin 0.3mg
Participants will receive Enavogli...